Business
AstraZeneca COVID-19 vaccine trial data results in revised efficacy rate – The Motley Fool Australia
AstraZeneca PLC (LON: AZN) has revised its COVID-19 vaccine efficacy rating after concluding a more extensive study previously done.
Home / Coronavirus News / AstraZeneca COVID-19 vaccine trial data results in revised efficacy rateThe Oxford-AstraZeneca PLC (LON: AZN) COVID-19 vaccine has travelled a bumpy road through its development and rollout. Marred with accusations of the vaccine causing blood clots, regulatory and government pressures have weighed on the drug developer and its acceptance.
According to the latest press release from AstraZeneca, the company has revised the vaccine’s efficacy from 79% to 76%, following…
-
Noosa News18 hours agoTwo in five Brisbane streets have no footpaths, with council building about 4km of new paths last year
-
General19 hours ago‘Genuinely historic’: Australia and PNG sign major deal
-
General22 hours agoWanted: an effective Opposition | The Spectator Australia
-
Noosa News17 hours agoWeather to warm up in Queensland, as more rain forecast for the north